The correlation between genetic polymorphisms of CYP3A and MDR1 and the blood drug concentrations of tacrolimus
XU Ya-fei
DONG Rui-hua
MA Jing-jie
QU Heng-yan
LIU Ze-yuan
Abstract：As a novel immunosuppressant, tacrolimus (FK506) is widely applied to prevent rejections after organ transplants. FK506 is mainly metabolized by cytochrome P450 (CYP450) 3A and transported by P-glycoprotein (P-gp). Genetic polymorphisms of CYP3A and MDR1 probably influence the expressions and bioactivity of CYP3A and P-gp, and then affect FK506 pharmacokinetics and finally may affect the blood drug concentrations of FK506. This article summarized the correlation between genetic polymorphisms of CYP3A and MDR1 and the blood drug concentrations of FK506 to guide the rational and individualized medication in clinic.
Keywords：TacrolimusBlood drug concentrationGene polymorphismCYP3AMDR1
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 59-62 )